Market revenue in 2024 | USD 426.2 million |
Market revenue in 2030 | USD 679.2 million |
Growth rate | 8.1% (CAGR from 2025 to 2030) |
Largest segment | Implantable cardioverter defibrillators |
Fastest growing segment | Cardiac Resynchronization therapy |
Historical data | 2018 - 2023 |
Base year | 2024 |
Forecast period | 2025 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Ventricular Assist Devices, Implantable Cardioverter Defibrillators, Pacemakers, Cardiac Resynchronization therapy, Counter Pulsation Devices |
Key market players worldwide | Medtronic PLC, Boston Scientific Corp, Abbott Laboratories, Jarvik Heart, ReliantHeart, Biotronik SE & Co., KG, Berlin Heart GmbH |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to congestive heart failure treatment devices market will help companies and investors design strategic landscapes.
Implantable cardioverter defibrillators was the largest segment with a revenue share of 34.61% in 2024. Horizon Databook has segmented the China congestive heart failure treatment devices market based on ventricular assist devices, implantable cardioverter defibrillators, pacemakers, cardiac resynchronization therapy, counter pulsation devices covering the revenue growth of each sub-segment from 2018 to 2030.
With the high unmet needs of a huge population base, the market is expected to witness profitable growth over the forecast period. Moreover, with many healthcare reforms in China, the market is expected to exhibit substantial growth. For instance, LifeSeeds, the China Rural Health Initiative is expected to provide healthcare access to unattended parts of china, thus opening up avenues for market players.
In addition, the Chinese market is affected by the centralized purchasing system, in effect since 2012, under the Regulations on Centralized Procurement of High-value Consumable Medical Supplies, which is impacting the price of interventional cardiovascular devices thus declining the profit margin of manufacturers.
Horizon Databook provides a detailed overview of country-level data and insights on the China congestive heart failure treatment devices market, including forecasts for subscribers. This country databook contains high-level insights into China congestive heart failure treatment devices market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account